表紙
市場調査レポート

OTC胃腸薬の世界市場 2015〜2019年

Global Gastrointestinal OTC Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 328830
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
OTC胃腸薬の世界市場 2015〜2019年 Global Gastrointestinal OTC Drugs Market 2015-2019
出版日: 2015年04月15日 ページ情報: 英文 101 Pages
概要

世界のOTC胃腸薬市場は、2014から2019年にかけて1.48%の年平均成長率 (CAGR) で成長する見通しです。

当レポートでは、世界のOTC胃腸薬市場について分析し、市場の概要や構造、市場規模の動向 (今後5年間の予測値)、医薬品の治療クラス・適応症・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 概要:OTC医薬品

  • OTC認可の規制経路
  • FDAのOTC医薬品認可プロセス
    • OTC NDA
    • OTC医薬品モノグラフ
    • 胃腸処方薬のOTC切換え

第7章 胃腸疾患の疫学

第8章 市場情勢

  • 市場概要
  • 市場規模・予測
  • 主な予測
  • ファイブフォース分析

第9章 市場区分:医薬品の治療クラス別

  • 胃酸分泌抑制剤
  • 胃酸中和剤
  • 便秘薬
  • 下痢止め薬
  • 制吐薬
  • その他

第10章 市場区分:適応症別

  • GRED (胃食道逆流症)
  • 便秘
  • 下痢
  • 乗り物酔いによる吐き気
  • 鼓腸

第11章 地域区分

  • 南北アメリカにおけるOTC胃腸薬市場
  • EMEA (欧州・中東・アフリカ) におけるOTC胃腸薬市場
  • APAC (アジア太平洋地域) におけるOTC胃腸薬市場

第12章 購入基準

第13章 市場の成長促進要因

第14章 促進要因とその影響力

第15章 市場の課題

第16章 促進要因・課題の影響力

第17章 市場の動向

第18章 市場動向とその影響

第19章 ベンダー情勢

  • 競合状況
  • 市場シェア分析
    • Bayer
    • GlaxoSmithKline
    • Johnson & Johnson
    • Perrigo
    • Pfizer
    • P&G
  • その他の有望ベンダー

第20章 主要ベンダーの分析

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Perrigo
  • Pfizer
  • P&G

第21章 関連レポート

図表一覧

目次
Product Code: IRTNTR5810

About gastrointestinal OTC drugs

OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country.

Technavio's analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the management of gastrointestinal disorders such as:

  • GERD/Heartburn
  • Constipation
  • Diarrhea
  • Nausea due to motion sickness
  • Flatulence

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also discusses the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio's report, Global Gastrointestinal OTC Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and EMEA and APAC; it also covers the global gastrointestinal OTC drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Perrigo
  • Pfizer
  • Procter & Gamble

Other Prominent Vendors

  • Abbott
  • Boehringer Ingelheim
  • C.B. Fleet
  • Nestle
  • Omega
  • Purdue Pharma
  • Reckitt Benckiser
  • Sanofi
  • Teva Pharmaceutical

Market driver

  • Increase in patient population
  • For a full, detailed list, view our report

Market challenge

  • High spending on advertisement
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Overview: OTC Drugs

  • 06.1. Regulatory pathways for OTC approval
  • 06.2. FDA OTC drug approval process
    • 06.2.1. OTC NDA
    • 06.2.2. OTC drug monograph
    • 06.2.3. Gastrointestinal prescription to OTC switch

07. Epidemiology of Gastrointestinal Disorders

08. Market Landscape

  • 08.1. Market overview
  • 08.2. Market size and forecast
  • 08.3. Top predictions
  • 08.4. Five forces analysis

09. Market Segmentation by Therapeutic Class of Drug

    • 09.1.1. Gastric acid reducers
    • 09.1.2. Gastric acid neutralizers
    • 09.1.3. Laxatives
    • 09.1.4. Antidiarrheals
    • 09.1.5. Antiemetics
    • 09.1.6. Others

10. Market Segmentation by Indication

    • 10.1.1. GERD
    • 10.1.2. Constipation
    • 10.1.3. Diarrhea
    • 10.1.4. Nausea caused by motion sickness
    • 10.1.5. Flatulence

11. Geographical Segmentation

  • 11.1. Gastrointestinal OTC drugs market in Americas
    • 11.1.1. Market size and forecast
  • 11.2. Gastrointestinal OTC drugs market in EMEA
    • 11.2.1. Market size and forecast
  • 11.3. Gastrointestinal OTC drugs market in APAC
    • 11.3.1. Market size and forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive scenario
    • 19.1.1. Key news
    • 19.1.2. Mergers and acquisitions
  • 19.2. Market share analysis 2014
    • 19.2.1. Bayer
    • 19.2.2. GlaxoSmithKline
    • 19.2.3. Johnson & Johnson
    • 19.2.4. Perrigo
    • 19.2.5. Pfizer
    • 19.2.6. P&G
  • 19.3. Other prominent vendors

20. Key Vendor Analysis

  • 20.1. Bayer
    • 20.1.1. Key facts
    • 20.1.2. Business overview
    • 20.1.3. Business segmentation by revenue 2014
    • 20.1.4. Business segmentation by revenue 2013 and 2014
    • 20.1.5. Geographical segmentation by revenue 2014
    • 20.1.6. Business strategy
    • 20.1.7. Recent developments
    • 20.1.8. SWOT analysis
  • 20.2. GlaxoSmithKline
    • 20.2.1. Key facts
    • 20.2.2. Business overview
    • 20.2.3. Business segmentation by revenue 2014
    • 20.2.4. Business segmentation by revenue 2013 and 2014
    • 20.2.5. Geographical segmentation by revenue 2014
    • 20.2.6. Business strategy
    • 20.2.7. Recent developments
    • 20.2.8. SWOT analysis
  • 20.3. Johnson & Johnson
    • 20.3.1. Key facts
    • 20.3.2. Business overview
    • 20.3.3. Business segmentation by revenue 2014
    • 20.3.4. Business segmentation by revenue 2013 and 2014
    • 20.3.5. Geographical segmentation by revenue 2014
    • 20.3.6. Business strategy
    • 20.3.7. Recent developments
    • 20.3.8. SWOT analysis
  • 20.4. Perrigo
    • 20.4.1. Key facts
    • 20.4.2. Business overview
    • 20.4.3. Business segmentation by revenue 2014
    • 20.4.4. Business segmentation by revenue 2013 and 2014
    • 20.4.5. Geographical segmentation by revenue 2014
    • 20.4.6. Business strategy
    • 20.4.7. Recent developments
    • 20.4.8. SWOT analysis
  • 20.5. Pfizer
    • 20.5.1. Key facts
    • 20.5.2. Business overview
    • 20.5.3. Business segmentation by revenue 2014
    • 20.5.4. Business segmentation by revenue 2013 and 2014
    • 20.5.5. Geographical segmentation by revenue 2014
    • 20.5.6. Business strategy
    • 20.5.7. Key developments
    • 20.5.8. SWOT analysis
  • 20.6. P&G
    • 20.6.1. Key facts
    • 20.6.2. Business overview
    • 20.6.3. Business segmentation by revenue 2014
    • 20.6.4. Business segmentation by revenue 2013 and 2014
    • 20.6.5. Geographical segmentation by revenue 2014
    • 20.6.6. Business strategy
    • 20.6.7. Recent developments
    • 20.6.8. SWOT analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market research methodology
  • Exhibit 2: Comparison between prescription and OTC drugs
  • Exhibit 3: Advantages and disadvantages of OTC drugs
  • Exhibit 4: Ways to establish an OTC drug in different markets
  • Exhibit 5: Key regulatory bodies for OTC approval
  • Exhibit 6: FDA OTC drug approval process
  • Exhibit 7: Comparison of NDA versus OTC monograph process
  • Exhibit 8: Mechanisms to amend an OTC drug monograph
  • Exhibit 9: Drugs underwent Rx-to-OTC switch in US
  • Exhibit 10: Global gastrointestinal OTC drugs market 2014-2019 ($ million)
  • Exhibit 11: Top predictions in global gastrointestinal OTC drugs market
  • Exhibit 13: Global gastrointestinal OTC drugs market by therapeutic class of drug
  • Exhibit 14: Global gastrointestinal OTC drugs market by therapeutic class of drug 2014
  • Exhibit 15: Global gastrointestinal OTC drugs market by indication
  • Exhibit 16: Segmentation of global gastrointestinal OTC drugs market by geography 2014
  • Exhibit 17: Segmentation of global gastrointestinal OTC drugs market by geography 2019
  • Exhibit 18: Gastrointestinal OTC drugs market in Americas 2014-2019 ($ million)
  • Exhibit 19: Gastrointestinal OTC drugs market in EMEA 2014-2019 ($ million)
  • Exhibit 20: Gastrointestinal OTC drugs market in APAC 2014-2019 ($ million)
  • Exhibit 21: Key takeaways: Bayer
  • Exhibit 22: Key takeaways: GlaxoSmithKline
  • Exhibit 23: Key takeaways: Johnson & Johnson
  • Exhibit 24: Key takeaways: Perrigo
  • Exhibit 25: Product portfolio matrix of major vendors
  • Exhibit 26: Key takeaways: Pfizer
  • Exhibit 27: Key takeaways: P&G
  • Exhibit 28: Bayer: business segmentation by revenue 2014
  • Exhibit 29: Bayer: business segmentation by revenue 2013 and 2014 (US$ billion)
  • Exhibit 30: Bayer: geographical segmentation by revenue 2014
  • Exhibit 31: GlaxoSmithKline: business segmentation by revenue 2014
  • Exhibit 32: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 33: GlaxoSmithKline: geographical segmentation by revenue 2014
  • Exhibit 34: Johnson & Johnson: business segmentation by revenue 2014
  • Exhibit 35: Johnson & Johnson: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 36: Johnson & Johnson: geographical segmentation by revenue 2014
  • Exhibit 37: Perrigo: business segmentation by revenue 2014
  • Exhibit 38: Perrigo: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 39: Perrigo: geographical segmentation by revenue 2014
  • Exhibit 40: Pfizer: business segmentation by revenue 2014
  • Exhibit 41: Pfizer: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 42: Pfizer: geographical segmentation by revenue 2014
  • Exhibit 43: P&G: business segmentation by revenue 2014
  • Exhibit 44: P&G: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 45: P&G: geographical segmentation by revenue 2014
Back to Top